Article Sidebar
Published:
May 8, 2017Article Details
Issue
Section
Articles
Material submitted for publication in the Journal of Endocrinology, Metabolism and Diabetes of South Africa (JEMDSA) is accepted provided it has not been published elsewhere. JEMDSA reserves copyright of the material published. Neither JEMDSA nor the Publisher may be held responsible for statements made by the authors.
Main Article Content
Review of once-monthly oral ibandronate and the use thereof
Abstract
An advisory board meeting of key opinion leaders was held in 2015 to discuss the clinical data on oral ibandronate in the treatment of postmenopausal osteoporosis.
Boniva 150 mg (ibandronate) oral once-monthly is indicated for the treatment of osteoporosis in postmenopausal women, in order to reduce the risk of vertebral fractures.1
